# ORAMED PHARMACEUTICALS INC. (ORMP) · Edgar & Edgarette company card

> Oramed Pharmaceuticals (ORMP) grew revenue 49.3% in FY2025 to $2 million, operating margin -754% against a -3.8% median for pharmaceutical preparations, equity 86.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1176309 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ORMP) · [JSON](https://www.pops4.com/boards/company/ORMP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 49.3% |
| Revenue growth per year | -5.5% |
| Operating margin | -754.4% (prior year -1176.8%) |
| Net margin | 3202.5% |
| Operating cash flow | −$9M |
| Capital spending | $9,000 |
| Free cash flow | −$9M |
| Cash | $46M |
| Long-term debt | — |
| Total assets | $231M |
| Total equity | $200M |
| Equity ÷ assets | 86.5% |
| Return on equity | 32.1% |
| Dividend per share | $0.25 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 7.8 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice in the last 12 months; operating cash flow was negative; operating loss: a margin of -754.4% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $2.0M (FY2025). Experience: revenue up 49.3% on the year, down 5.5% a year over 5 years; operating margin -754.4%, up from -1176.8%. Soundness: equity 86.5% of assets, return on equity 32.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.8M and $3.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -754.4% against a -3.8% median; growth 49.3% against 13.7%.

Range logged 2026-09-20, receipt 326cc45afbc2eb9b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026057722/0001213900-26-057722-index.htm))
- Item 5.02 Director or officer change: 1, latest 2025-12-31 ([filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390025127133/0001213900-25-127133-index.htm))

## Recent filings

- 8-K · filed 2026-09-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/0001213900-26-100929-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026087361/0001213900-26-087361-index.htm)
- DEF 14A · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026084609/0001213900-26-084609-index.htm)
- 8-K · filed 2026-06-30 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026073709/0001213900-26-073709-index.htm)
- 10-Q · filed 2026-05-19 · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026059112/0001213900-26-059112-index.htm)
- 8-K · filed 2026-03-31 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets · [filing](https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/0001213900-26-037474-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001176309.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1176309

## Cite

POPS4, Edgar & Edgarette: ORAMED PHARMACEUTICALS INC. (ORMP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ORMP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.